Adherence to long-term adjuvant hormonal therapy for breast cancer

References

• Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Canadian Cancer Society. Toronto, ON, Canada (2011).
   Google Scholar
• Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord.8(3), 229–239 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov.2(3), 205–213 (2003).
   PubMed Web of Science ®Google Scholar
• Jordan C. Tamoxifen (IC146, 474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol.147(Suppl. 1), S269–S276 (2006).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet353(9169), 1993–2000 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res. Treat.76(1), 27–36 (2002).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann. Oncol.18(Suppl. 8), viii26– viii35 (2007).
   PubMed Web of Science ®Google Scholar
• Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J. Natl Compr. Canc. Netw.4(10), 971–979 (2006).
   PubMedGoogle Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol.28(23), 3784–3796 (2010).
   PubMed Web of Science ®Google Scholar
• McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br. J. Cancer99(11), 1763–1768 (2008).
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat.126(2), 529–537 (2011) .
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J. Clin.59(1), 56–66 (2009).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology71(1–2), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer109(5), 832–839 (2007).
   PubMed Web of Science ®Google Scholar
• Cluze C, Rey D, Huiart L et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann. Oncol. doi:10.1093/annonc/mdr330 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med. Care.45(5), 431–439 (2007).
   PubMed Web of Science ®Google Scholar
• Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J. Clin. Oncol.27(21), 3445–3451 (2009).
   PubMed Web of Science ®Google Scholar
• Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J. Clin. Oncol.26(4), 549–555 (2008).
   PubMed Web of Science ®Google Scholar
• Chan A, Speers C, O’Reilly S, Pickering R, Chia S. Adherence of adjuvant hormonal therapies in post-menopausal hormone receptor positive (HR+) early stage breast cancer: a population based study from British Columbia. Cancer Res.69(24), 36 (2009).
   Google Scholar
• Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J. Clin. Oncol.28(27), 4120–4128 (2010).
   PubMed Web of Science ®Google Scholar
• Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br. J. Cancer104, 1558–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res. Treat.130(2), 681–689 (2011).
   PubMedGoogle Scholar
• Neugut AI, Subar M, Wilde ET et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J. Clin. Oncol.29(18), 2534–2542 (2011).
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol.26(4), 556–562 (2008).
   PubMed Web of Science ®Google Scholar
• Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res. Treat.125(1), 191–200 (2011).
   PubMed Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol.20(3), 431–436 (2009).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies – evidence for action. WHO, Geneva, Switzerland (2003).
   Google Scholar
• Garreau J, DeLaMelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am. J. Surg.192(4), 496–498 (2006).
   PubMed Web of Science ®Google Scholar
• Winters L, Habin K, Flanagan J, Cashavelly BJ. “I feel like I am 100 years old!” managing arthralgias from aromatase inhibitors. Clin. J. Oncol. Nurs.14(3), 379–382 (2010).
   PubMedGoogle Scholar
• Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin. Breast Cancer8(2), 155–161 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J. Support Oncol.5(3), 139–143 (2007).
   PubMedGoogle Scholar
• Miaskowski C, Shockney L, Chlebowski RT. Adherence to endocrine therapy for breast cancer. Clin. J. Oncol. Nurs.12(2), 213–221 (2008).
   PubMed Web of Science ®Google Scholar
• Winkeljohn D. Adherence to oral cancer therapies: nursing interventions. Clin. J. Oncol. Nurs.14(4), 461–466 (2010).
   PubMed Web of Science ®Google Scholar
• Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res. Treat.126(2), 295–310 (2011).
   PubMedGoogle Scholar
• Levine AM, Richardson JL, Marks G et al. Compliance with oral drug therapy in patients with hematologic malignancy. J. Clin. Oncol.5(9), 1469–1476 (1987).
   PubMed Web of Science ®Google Scholar
• Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA296(21), 2563–2571 (2006).
   PubMed Web of Science ®Google Scholar
• Ell K, Vourlekis B, Xie B et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer115(19), 4606–4615 (2009).
   PubMed Web of Science ®Google Scholar